Y-mAbs Therapeutics Beheer

Beheer criteriumcontroles 2/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Mike Rossi

Algemeen directeur

US$3.1m

Totale compensatie

Percentage CEO-salaris	3.5%
Dienstverband CEO	1.1yrs
Eigendom CEO	n/a
Management gemiddelde ambtstermijn	3.7yrs
Gemiddelde ambtstermijn bestuur	7yrs

Recente managementupdates

Recent updates

We Think Y-mAbs Therapeutics (NASDAQ:YMAB) Can Afford To Drive Business Growth

Dec 10

The Market Doesn't Like What It Sees From Y-mAbs Therapeutics, Inc.'s (NASDAQ:YMAB) Revenues Yet As Shares Tumble 26%

Nov 19

Y-mAbs Therapeutics: Slow But Steady Prospect In Rare Cancers

Oct 21

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Held Back By Insufficient Growth Even After Shares Climb 33%

Sep 12

Revisiting Y-mAbs After The Summer Oncology Meeting (Rating Upgrade)

Aug 12

We're Not Worried About Y-mAbs Therapeutics' (NASDAQ:YMAB) Cash Burn

Jul 15

Investors Don't See Light At End Of Y-mAbs Therapeutics, Inc.'s (NASDAQ:YMAB) Tunnel And Push Stock Down 29%

Jun 02

Y-mAbs: There's A Ceiling Here Somewhere

May 09

We're Not Worried About Y-mAbs Therapeutics' (NASDAQ:YMAB) Cash Burn

Mar 14

Y-mAbs Therapeutics, Inc.'s (NASDAQ:YMAB) Shares Bounce 66% But Its Business Still Trails The Industry

Feb 17

Party Time: Brokers Just Made Major Increases To Their Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Earnings Forecasts

May 13

Y-mAbs Therapeutics, Inc.'s (NASDAQ:YMAB) Price Is Right But Growth Is Lacking After Shares Rocket 104%

Apr 17

Y-mAbs Therapeutics (NASDAQ:YMAB) Will Have To Spend Its Cash Wisely

Mar 22

We Think Y-mAbs Therapeutics (NASDAQ:YMAB) Needs To Drive Business Growth Carefully

Dec 13

Analysts Just Shaved Their Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Forecasts Dramatically

Aug 13

Y-mAbs gets FDA nod to begin phase 1 study of GD2-SADA for certain cancers

Jul 12

Y-mAbs Therapeutics: Steady, Small Steps Targeting Rare Cancers

May 30

Analyse CEO-vergoeding

Hoe is Mike Rossi's beloning veranderd ten opzichte van Y-mAbs Therapeutics's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Sep 30 2024	n/a	n/a	-US$24m
Jun 30 2024	n/a	n/a	-US$25m
Mar 31 2024	n/a	n/a	-US$22m
Dec 31 2023	US$3m	US$110k	-US$21m

Compensatie versus markt: De totale vergoeding ($USD 3.11M ) Mike } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 2.16M ).

Compensatie versus inkomsten: Er zijn onvoldoende gegevens om de beloning van Mike te vergelijken met de prestaties van het bedrijf.

CEO

Mike Rossi (53 yo)

1.1yrs

Tenure

US$3,110,553

Compensatie

Mr. Michael Rossi, also known as Mike, serves as Chief Executive Officer, President & Director of Y-mAbs Therapeutics, Inc. since November 06, 2023. He has been Director at Nucleus RadioPharma, Inc. He had...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Michael Rossi	CEO, President & Director	1.1yrs	US$3.11m	geen gegevens
Thomas Gad	Founder	9.7yrs	US$2.45m	0.58% $ 2.2m
Susan Smith	Senior VP & Chief Commercial Officer	2.9yrs	US$887.28k	0.0095% $ 35.2k
Peter Pfreundschuh	CFO & Treasurer	less than a year	geen gegevens	geen gegevens
Joris Wiel Wilms	Senior VP & COO	7.1yrs	geen gegevens	0.0021% $ 7.8k
Torben Lund-Hansen	Senior VP & CTO	8.9yrs	geen gegevens	0.12% $ 427.2k
Courtney Dugan	Vice President of Investor Relations	no data	geen gegevens	geen gegevens
Vignesh Rajah	Senior VP & Chief Medical Officer	4.5yrs	US$724.92k	0.019% $ 70.3k
Norman D. LaFrance	Chief Development Officer	less than a year	geen gegevens	geen gegevens

3.7yrs

Gemiddelde duur

54.5yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van YMAB wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.7 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Michael Rossi	CEO, President & Director	1.1yrs	US$3.11m	geen gegevens
Thomas Gad	Founder	9.7yrs	US$2.45m	0.58% $ 2.2m
James Healy	Independent Chairman of the Board	7.1yrs	US$184.31k	0.063% $ 232.7k
David Gill	Independent Director	7yrs	US$180.56k	0.0052% $ 19.3k
Mary Tagliaferri	Director	less than a year	geen gegevens	0% $ 0
Johan Wedell-Wedellsborg	Independent Director	9.3yrs	US$158.06k	0.0052% $ 19.3k
Ashutosh Tyagi	Independent Director	7.1yrs	US$158.06k	0.0052% $ 19.3k
Laura Hamill	Independent Director	4.5yrs	US$168.06k	0.0052% $ 19.3k

7.0yrs

Gemiddelde duur

56yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van YMAB wordt beschouwd als ervaren (gemiddelde ambtstermijn 7 jaar).

Bedrijfsanalyse en status van financiële gegevens

Gegevens	Laatst bijgewerkt (UTC-tijd)
Bedrijfsanalyse	2024/12/22 03:16
Aandelenkoers aan het einde van de dag	2024/12/20 00:00
Inkomsten	2024/09/30
Jaarlijkse inkomsten	2023/12/31

Gegevensbronnen

De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.

Pakket	Gegevens	Tijdframe	Voorbeeld Amerikaanse bron ^*
Financiële gegevens bedrijf	10 jaar	Resultatenrekening Kasstroomoverzicht Balans	SEC-formulier 10-K SEC-formulier 10-Q
Consensus schattingen analisten	+3 jaar	Financiële prognoses Koersdoelen analisten	Onderzoeksrapporten van analisten Blue Matrix
Marktprijzen	30 jaar	Aandelenprijzen Dividenden, splitsingen en acties	ICE Marktgegevens SEC-formulier S-1
Eigendom	10 jaar	Top aandeelhouders Handel met voorkennis	SEC-formulier 4 SEC-formulier 13D
Beheer	10 jaar	Leiderschapsteam Raad van bestuur	SEC-formulier 10-K SEC-formulier DEF 14A
Belangrijkste ontwikkelingen	10 jaar	Bedrijfsaankondigingen	SEC-formulier 8-K

^* voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige regelgevingsformulieren en bronnen gebruikt.

Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Lees hier meer.

Analysemodel en Snowflake

Details van het analysemodel dat is gebruikt om dit rapport te genereren, zijn beschikbaar op onze Github-pagina. We hebben ook handleidingen voor het gebruik van onze rapporten en tutorials op Youtube.

Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.

Industrie en sector

Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op .

Bronnen van analisten

Y-mAbs Therapeutics, Inc. wordt gevolgd door 21 analisten. 11 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.

Analist	Instelling
Peter Lawson	Barclays
Evan Seigerman	BMO Capital Markets Equity Research
Etzer Darout	BMO Capital Markets Equity Research

Y-mAbs Therapeutics Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Recente managementupdates

Founder recently sold US$1.3m worth of stock

Founder notifies of intention to sell stock

Senior VP & CTO notifies of intention to sell stock

Y-mAbs Therapeutics, Inc. Announces the Appointment of Peter Pfreundschuh as Chief Financial Officer

Founder notifies of intention to sell stock

Founder recently sold US$841k worth of stock

Recent updates

We Think Y-mAbs Therapeutics (NASDAQ:YMAB) Can Afford To Drive Business Growth

The Market Doesn't Like What It Sees From Y-mAbs Therapeutics, Inc.'s (NASDAQ:YMAB) Revenues Yet As Shares Tumble 26%

Third quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Y-mAbs Therapeutics, Inc. Reiterates Earnings Guidance for the Year 2024

Y-mAbs Therapeutics, Inc. to Report Q3, 2024 Results on Nov 08, 2024

Y-mAbs Therapeutics: Slow But Steady Prospect In Rare Cancers

Founder recently sold US$1.3m worth of stock

Founder notifies of intention to sell stock

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Held Back By Insufficient Growth Even After Shares Climb 33%

Senior VP & CTO notifies of intention to sell stock

Consensus EPS estimates fall by 15%

Second quarter 2024 earnings: EPS misses analyst expectations

Y-mAbs Therapeutics, Inc. Provides Earnings Guidance for the Year 2024

Revisiting Y-mAbs After The Summer Oncology Meeting (Rating Upgrade)

Y-mAbs Therapeutics, Inc. to Report Q2, 2024 Results on Aug 12, 2024

Pomerantz LLP Announces Proposed Class Action Settlement on Behalf of Purchasers of Stock of Y-mAbs Therapeutics, Inc

We're Not Worried About Y-mAbs Therapeutics' (NASDAQ:YMAB) Cash Burn

Y-mAbs Therapeutics, Inc.(NasdaqGS:YMAB) dropped from Russell Small Cap Comp Value Index

Y-mAbs Therapeutics, Inc. Announces the Appointment of Peter Pfreundschuh as Chief Financial Officer

Founder notifies of intention to sell stock

Founder recently sold US$841k worth of stock

Y-mAbs Therapeutics, Inc. Appoints Norman LaFrance as Chief Development Officer

Investors Don't See Light At End Of Y-mAbs Therapeutics, Inc.'s (NASDAQ:YMAB) Tunnel And Push Stock Down 29%

Executive VP notifies of intention to sell stock

Y-mAbs Therapeutics, Inc. Announces New Interim Analysis of Phase 2 Data for Naxitamab At 2024 Asco Annual Meeting

Founder recently sold US$396k worth of stock

Founder notifies of intention to sell stock

Y-mAbs: There's A Ceiling Here Somewhere

First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Y-mAbs Therapeutics, Inc., Annual General Meeting, Jun 11, 2024

Y-mAbs Therapeutics, Inc. to Report Q1, 2024 Results on May 07, 2024

Y-mAbs Therapeutics, Inc. Announces Resignation of Bo Kruse as Executive Vice President, Secretary and Treasurer, Effective July 31, 2024

Y-mAbs Therapeutics Announces Resignation of Bo Kruse as Chief Financial Officer

We're Not Worried About Y-mAbs Therapeutics' (NASDAQ:YMAB) Cash Burn

Consensus estimates of losses per share improve by 42%

Y-mAbs Therapeutics, Inc. Appoints Mary Tagliaferri to Its Board of Directors

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Y-mAbs Therapeutics, Inc. Provides Earnings Guidance for the Year 2024

Y-mAbs Therapeutics, Inc. to Report Q4, 2023 Results on Feb 29, 2024

Y-mAbs Therapeutics, Inc.'s (NASDAQ:YMAB) Shares Bounce 66% But Its Business Still Trails The Industry

Price target increased by 9.3% to US$13.67

Y-mAbs Therapeutics: A Monoclonal Antibody Play

Founder exercised options to buy US$370k worth of stock.

Founder recently sold US$1.0m worth of stock

Founder notifies of intention to sell stock

Founder recently sold US$795k worth of stock

Founder notifies of intention to sell stock

Y-mAbs Therapeutics, Inc. Reiterates Financial Guidance for the Year 2023

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

We're Not Very Worried About Y-mAbs Therapeutics' (NASDAQ:YMAB) Cash Burn Rate

Y-mAbs Therapeutics, Inc. to Report Q3, 2023 Results on Nov 13, 2023

Y-mAbs Therapeutics, Inc. Announces Chief Executive Officer Changes, Effective from November 6, 2023

Y-mAbs Therapeutics, Inc. Announces Publication of Naxitamab-Based Chemoimmunotherapy in Patients with Chemoresistant High-Risk Neuroblastoma

Consensus EPS estimates upgraded to US$0.70 loss

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Y-mAbs Therapeutics, Inc. to Report Q2, 2023 Results on Aug 10, 2023

New major risk - Revenue and earnings growth

We Think Y-mAbs Therapeutics (NASDAQ:YMAB) Can Afford To Drive Business Growth

Y-mAbs Therapeutics, Inc. Announces DANYELZA (naxitamab-gqgk) for the Treatment of High-Risk Neuroblastoma Approved in Brazil

Consensus revenue estimates increase by 27%

Party Time: Brokers Just Made Major Increases To Their Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Earnings Forecasts

Price target increased by 11% to US$10.50

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Y-mAbs Therapeutics, Inc. Updates Financial Guidance for the Full-Year 2023

Y-mAbs Therapeutics, Inc.'s (NASDAQ:YMAB) Price Is Right But Growth Is Lacking After Shares Rocket 104%

Consensus estimates of losses per share improve by 14%

Price target decreased by 15% to US$9.14

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Y-mAbs Therapeutics (NASDAQ:YMAB) Will Have To Spend Its Cash Wisely